Essential hypertension, progressive renal disease, and uric acid:: A pathogenetic link?

被引:211
作者
Johnson, RJ
Segal, MS
Srinivas, T
Ejaz, A
Mu, W
Roncal, C
Sánchez-Lozada, LG
Gersch, M
Rodriguez-Iturbe, B
Kang, DH
Acosta, JH
机构
[1] Univ Florida, Nephrol Sect, Div Nephrol Hypertens & Transplantat, Gainesville, FL 32610 USA
[2] Inst Nacl Cardiol Ignacio Chavez, Dept Nephrol, Mexico City, DF, Mexico
[3] Univ Hosp, Renal Serv Lab, Maracaibo, Venezuela
[4] Inst Invest Biomed, Maracaibo, Venezuela
[5] Ewha Univ, Coll Med, Div Nephrol, Seoul, South Korea
来源
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 2005年 / 16卷 / 07期
关键词
D O I
10.1681/ASN.2005010063
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Hypertension and hypertension-associated ESRD are epidemic in society. The mechanisms responsible for renal progression in mild to moderate hypertension and those groups most at risk need to be identified. Historic, epidemiologic, clinical, and experimental studies on the pathogenesis of hypertension and hypertension-associated renal disease are reviewed and an overview/hypothesis for the mechanisms involved in renal progression is presented. There is increasing evidence that hypertension may exist in one of two forms/stages. The first stage, most commonly observed in early or borderline hypertension, is characterized by salt-resistance, normal or only slightly decreased GFR, relatively normal or mild renal arteriolosclerosis, and normal renal autoregulation. This group is at minimal risk for renal progression. The second stage, characterized by salt-sensitivity, renal arteriolar disease, and blunted renal autoregulation, defines a group at highest risk for the development of microalbuminuria, albuminuria, and progressive renal disease. This second stage is more likely to be observed in blacks, in subjects with gout or hyperuricemia, with low level lead intoxication, or with severe obesity/metabolic syndrome. The two major mechanistic pathways for causing impaired autoregulation at mild to moderate elevations in BP appear to be hyperuricemia and/or low nephron number. Understanding the pathogenetic pathways mediating renal progression in hypertensive subjects should help identify those subjects at highest risk and may provide insights into new therapeutic maneuvers to slow or prevent progression.
引用
收藏
页码:1909 / 1919
页数:11
相关论文
共 172 条
[1]  
Morsell J.A., The problem of hypertension: A critical review of the literature dealing with its extent, A Symposium on Essential Hypertension
[2]  
An Epidemiologic Approach to the Elucidation of Its Natural History in Man, pp. 26-49, (1951)
[3]  
Fields L.E., Burt V.L., Cutler J.A., Hughes J., Roccella E.J., Sorlie P., The Burden of adult hypertension in the United States 1999 to 2000. A rising tide, Hypertension, 44, pp. 398-404, (2004)
[4]  
Robinson S.C., Brucer M., Range of normal blood pressure. A statistical and clinical study of 11,383 persons, Arch Int Med, 64, pp. 409-444, (1939)
[5]  
Johnson R.J., Srinivas T., Cade J.R., Rideout B.A., Oliver W.J., Uric acid, evolution and primitive cultures, Semin Nephrol, 25, pp. 3-8, (2005)
[6]  
United States Renal Data System 2003 Annual Data Report: Atlas of end-stage renal disease in the United States, Am J Kid Dis, 42, SUPPL. 5, (2003)
[7]  
Beevers D.G., Lip G.Y., Does nonmalignant essential hypertension cause renal damage? A clinician's view, J Hum Hypertens, 10, pp. 695-699, (1996)
[8]  
Rostand S.G., Is renal failure caused by primary hypertension? Why does the controversy continue?, Nephrol Dial Transpl, 13, pp. 3007-3010, (1998)
[9]  
Moyer J.H., Heider C., Pevey K., Ford R.V., The effect of treatment on the vascular deterioration associated with hypertension, with particular emphasis on renal function, Am J Med, 24, pp. 177-192, (1958)
[10]  
Klag M.J., Whelton P.K., Randall B.L., Neaton J.D., Brancati F.L., Stamler J., End-stage renal disease in African-American and white men. 16-Year MRFIT findings, JAMA, 277, pp. 1293-1298, (1997)